Neuroendocrine Neoplasms: Radioligand Therapy Advances While Combination Strategies Show Limited Benefit

A 'Year in Review' report highlights evolving treatment landscapes for neuroendocrine neoplasms (NETs), noting a rising incidence of these cancers, primarily driven by early-stage, low-grade disease. The review emphasizes the expansion of radioligand therapy options, including new lutetium Lu 177 products and alpha emitters. However, it also points out that combination strategies have not significantly improved outcomes compared to radioligand therapy alone, and checkpoint inhibitors show limited activity in unselected neuroendocrine carcinoma.